Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer
This was a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the anti- programmed cell death-1(PD-1) monoclonal antibody BGB-A317 in participants with PD-L1+, locally advanced or metastatic Urothelial Bladder Cancer (UBC) who have progressed during or following a platinum-containing regimen
Locally Advanced or Metastatic Urothelial Bladder Cancer
DRUG: Tislelizumab
Objective Response Rate (ORR) as Assessed by Independent Review Committee (IRC), ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) assessed by Independent Review Committee (IRC) using RECIST version 1.1, From the date of first dose up to approximately 2 years and 2 months
Duration of Response (DOR) as Assessed by IRC, DOR - defined as the time from the first determination of a confirmed objective response by IRC according to RECIST version 1.1 until the first documentation of progression or death, whichever comes first, From the date of first dose up to approximately 2 years and 2 months|Progression-Free Survival (PFS) as Assessed by IRC, PFS is defined as the time from the date of first dose of study drug to the date of first documentation of disease progression assessed by IRC using RECIST version 1.1 or death, whichever occurs first, From the date of first dose up to approximately 2 years and 2 months|Disease Control Rate (DCR) as Assessed by IRC, DCR is defined as the percentage of participants who achieve CR, PR and stable disease (SD) assessed by IRC using RECIST version 1.1, From the date of first dose up to approximately 2 years and 2 months|Overall Survival (OS), OS - defined as the time from the date of first dose of study drug until the date of death from any cause, From the date of first dose up to approximately 2 years and 2 months|ORR as Assessed by the Investigators, ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) as assessed by the investigators per RECIST version 1.1 and immune related RECIST (irRECIST), From the date of first dose up to approximately 2 years and 2 months|DOR as Assessed by Investigators Per RECIST Version 1.1 and irRECIST, DOR is defined as the time from the first determination of a confirmed objective response by the investigator according to RECIST version 1.1 and irRECIST until the first documentation of progression or death, whichever comes first, From the date of first dose up to approximately 2 years and 2 months|PFS as Assessed by Investigators Per RECIST Version 1.1 and irRECIST, PFS is defined as the time from the date of first dose of study drug to the date of first documentation of disease progression assessed by the investigator according to RECIST version 1.1 and irRECIST until the first documentation of progression or death, whichever comes first, From the date of first dose up to approximately 2 years and 2 months|DCR as Assessed by Investigators Per RECIST Version 1.1 and irRECIST, DCR is defined as the percentage of participants who achieve CR, PR and stable disease (SD) assessed by investigators per RECIST version 1.1 and irRECIST, From the date of first dose up to approximately 2 years and 2 months|Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), TEAE is defined as an adverse event (AE) that had an onset date or a worsening in severity from baseline pre-treatment) on or after the first dose of study drug up to 30 days following study drug .discontinuation. An SAE is any untoward medical occurrence that, at any dose that results in death or is life-threatening., From the date of first dose until End of Study (approximately 3 years and 9 months)
This was a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the anti- programmed cell death-1(PD-1) monoclonal antibody BGB-A317 in participants with PD-L1+, locally advanced or metastatic Urothelial Bladder Cancer (UBC) who have progressed during or following a platinum-containing regimen